Press Release RSS Feed (opens in new window)

Press Releases

Press release year list 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
December 20, 2017
Novocure to Participate in 36th Annual J.P. Morgan Healthcare Conference
December 19, 2017
JAMA Publishes Final Analysis of EF-14 Phase 3 Pivotal Trial of Optune® Together with Temozolomide Demonstrating Unprecedented Survival Results for Newly Diagnosed Glioblastoma
December 18, 2017
Novocure Receives FDA IDE Approval for its PANOVA 3 Phase 3 Pivotal Clinical Trial in Advanced Pancreatic Cancer
December 1, 2017
Novocure Receives Reimbursement Approval for Optune® in Japan for the Treatment of Newly Diagnosed Glioblastoma
November 22, 2017
Novocure to Present at Two Upcoming Investor Conferences in December
November 17, 2017
Patients Who Used Optune® More Than 90 Percent of the Time Had the Greatest Chance of Survival in Novocure’s EF-14 Trial: A Median Survival of 24.9 Months from Randomization and a Five-Year Survival of 29.3 Percent
November 13, 2017
Novocure Announces 28 Presentations on Tumor Treating Fields from Externally Led Clinical Research and Analysis at 22nd Annual Meeting of the Society for Neuro-Oncology
November 9, 2017
Novocure Announces 10 Presentations on Simulation Studies Aiming to Optimize Treatment Delivery of Tumor Treating Fields at 22nd Annual Meeting of the Society for Neuro-Oncology
November 8, 2017
Novocure Announces 13 Preclinical Presentations Highlighting Data on Tumor Treating Fields’ Mechanism of Action at 22nd Annual Meeting of the Society for Neuro-Oncology
November 6, 2017
Novocure Announces Six Clinical Presentations on Novocure’s Phase 3 Pivotal EF-14 Trial Data in Newly Diagnosed Glioblastoma at 22nd Annual Meeting of the Society for Neuro-Oncology
October 26, 2017
Novocure Reports Third Quarter 2017 Financial Results and Provides Company Update
October 16, 2017
Novocure Announces Data Presentations at the IASLC 18th World Conference on Lung Cancer
October 2, 2017
Novocure to Report Third Quarter 2017 Financial Results
September 24, 2017
Combination of Optune® with Temozolomide Demonstrates Unprecedented Five-Year Survival for Newly Diagnosed Glioblastoma Patients
September 22, 2017
Novocure Announces Data Presentations at the American Society for Radiation Oncology’s 2017 Annual Meeting
September 6, 2017
Novocure Announces Data Presentations at the ESMO 2017 Congress
September 5, 2017
German Federal Joint Committee Announces Decision to Support a Clinical Trial to Study Optune® for the Treatment of Newly Diagnosed Glioblastoma
August 24, 2017
Novocure to Present at Two Upcoming Investor Conferences in September
August 8, 2017
Novocure™ Announces National Reimbursement for Optune® in Austria
August 2, 2017
Novocure to Present at the 2017 Wedbush PacGrow Healthcare Conference
July 27, 2017
Novocure Reports Second Quarter 2017 Financial Results and Provides Company Update
July 24, 2017
Novocure™ Announces a Phase 1b Clinical Trial to Evaluate the Safety of Marizomib and Temozolomide in Combination with Optune® as Adjuvant Therapy in Patients with Glioblastoma
July 12, 2017
Novocure’s Optune® Now Available at More Than 600 Cancer Treatment Centers in the U.S.
July 11, 2017
Data on Delivery of Tumor Treating Fields to be Presented at the 39th Annual International Conference of the IEEE Engineering in Medicine and Biology Society
June 30, 2017
Novocure to Report Second Quarter 2017 Financial Results
June 28, 2017
Novocure to Present Three Abstracts on Tumor Treating Fields and Pancreatic Cancer at the European Society for Medical Oncology 19th World Congress on Gastrointestinal Cancer
June 13, 2017
Novocure Announces Change to Presentation Time at the JMP Securities 2017 Life Sciences Conference
June 8, 2017
First Patient Enrolled in RTOG Trial of Optune® together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma
June 5, 2017
Health Care Service Corporation Issues Positive Coverage Decision for Optune
June 2, 2017
Novocure to Present at the JMP Securities 2017 Life Sciences Conference
May 15, 2017
Novocure™ Receives Humanitarian Use Device Designation for Treatment of Pleural Mesothelioma
May 11, 2017
Martin J. Madden Joins Novocure Board of Directors
May 8, 2017
Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Delayed Decline in Several Health-Related Quality of Life Scales Compared to Temozolomide Alone for Newly Diagnosed Glioblastoma Patients
May 4, 2017
Novocure™ Announces Opening of Two Pilot Trials to Evaluate the Use of TTFields for Pediatric Gliomas
May 1, 2017
Novocure to Present at Three Upcoming Investor Conferences in May
May 1, 2017
Novocure™ Announces Data Presentations at the World Federation of Neuro-oncology Societies 5th Quadrennial Meeting
April 27, 2017
Novocure Reports First Quarter 2017 Financial Results and Provides Company Update
April 19, 2017
Novocure™ Announces Four Presentations on Tumor Treating Fields at the American Academy of Neurology Annual Meeting in Boston
April 17, 2017
CNS Oncology Publishes Data Suggesting Survival Benefit of Optune™ in Combination with Second Line Chemotherapies after Glioblastoma Recurrence
April 2, 2017
Combination of Optune™ with Standard of Care Chemotherapy, Temozolomide, Provides Landmark Five-Year Survival Rates for Newly Diagnosed Glioblastoma Patients
March 31, 2017
Combination of Tumor Treating Fields with Paclitaxel may Improve Survival of Patients with Recurrent Ovarian Cancer
March 31, 2017
Combination of Tumor Treating Fields with Standard of Care Therapies, Nab-Paclitaxel and Gemcitabine, Suggests Improved Survival of Patients with Advanced Pancreatic Cancer
March 31, 2017
Novocure Enrolls Last Patient in STELLAR Trial Testing Tumor Treating Fields in Combination with Standard of Care Chemotherapy in Mesothelioma
March 28, 2017
Novocure to Report First Quarter 2017 Financial Results
March 28, 2017
Novocure to Present at the 16th Annual Needham & Company Healthcare Conference
March 20, 2017
Novocure Receives MHLW Approval for Second Generation Optune® in Japan
March 1, 2017
Novocure Announces Data Presentations at the American Association for Cancer Research Annual Meeting 2017
February 23, 2017
Novocure Announces Departure of Chief Commercial Officer
February 23, 2017
Novocure Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Company Update
February 15, 2017
First Patient Enrolled in Novocure’s Phase 3 Pivotal LUNAR Trial Testing Tumor Treating Fields for the Treatment of Advanced Non-Small Cell Lung Cancer After Failing Platinum-Based Therapy
February 7, 2017
Novocure to Participate in the BIO 2017 CEO & Investor Conference
January 24, 2017
Novocure to Participate in Noble Capital Markets’ 13th Annual Investor Conference
January 19, 2017
Novocure’s Optune® Now Available at 500 Cancer Treatment Centers in the U.S.
January 10, 2017
Novocure Announces Preliminary Fourth Quarter and Full Year 2016 Operating Statistics
January 10, 2017
Novocure to Report Fourth Quarter and Full Year 2016 Financial Results